The average tumor volume measured for VEGFR-2 sequence-specific siRNA-treated group was approximately 100 mm3, whereas in siLacZ-treated and control groups, the mean volumes were 1700 mm3 and 1200 mm3 respectively, demonstrating that RPP-VEGFR-2 siRNA reduced 91.67% of tumor volume in comparison to the control groups [100]. The gene discussed is KDR; the disease is neoplasm.